Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 16.7 kDa. The protein migrates as 25-29 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human TSLP (R127A, R130A) Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
The purity of Human TSLP (R127A, R130A) Protein, His Tag (Cat. No. TSP-H52Ha) is more than 90% and the molecular weight of this protein is around 18-26 kDa verified by SEC-MALS.
Immobilized Human TSLP R, Fc Tag (Cat. No. TSR-H525a) at 5 μg/mL (100 μL/well) can bind Human TSLP (R127A, R130A), His Tag (Cat. No. TSP-H52Ha) with a linear range of 3-50 ng/mL (QC tested).
Immobilized Human TSLP (R127A, R130A), His Tag (Cat. No. TSP-H52Ha) at 1 μg/mL (100 μL/well) can bind Anti-TSLP, Human IgG2 with a linear range of 0.4-3 ng/mL (Routinely tested).
Captured Human TSLP (R127A, R130A), His Tag (Cat. No. TSP-H52Ha) on CM5 Chip via anti-His antibody, can bind Human TSLP R, Fc Tag (Cat. No. TSR-H525a) with an affinity constant of 4.22 nM as determined in SPR assay (Biacore T200) (Routinely tested).
Loaded Human TSLP R, Fc Tag (Cat. No. TSR-H525a) on Protein A Biosensor, can bind Human TSLP (R127A, R130A), His Tag (Cat. No. TSP-H52Ha) with an affinity constant of 16 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Monoclonal Anti-Human TSLP Antibody, Human IgG2 on AHC Biosensor, can bind Human TSLP (R127A, R130A), His Tag (Cat. No. TSP-H52Ha) with an affinity constant of 0.153 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
2e5 of Human TSLP R (Luc) HEK293 Reporter Cells were stained with 100 μL of 1 μg/mL of Human TSLP (R127A, R130A) Protein, His Tag (Cat. No. TSP-H52Ha) and negative control protein respectively, washed and then followed by PE anti-His Tag Antibody and analyzed with FACS (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tezepelumab | AMG-157; MEDI-9929 | Approved | Amgen Inc | Tezspire | United States | Asthma | Astrazeneca Ab | 2021-12-17 | Eosinophilic Esophagitis; Hypersensitivity; Dermatitis, Atopic; Hypersensitivity, Immediate; Bronchial Diseases; Pulmonary Disease, Chronic Obstructive; Respiratory Hypersensitivity; Sinusitis; Asthma; Granulomatosis with Polyangiitis; Lung Diseases; Immune System Diseases; Chronic Urticaria; Respiratory Tract Diseases; Nasal Polyps; Anaphylaxis; Carcinoma; Lung Diseases, Obstructive | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Bosakitug | BSI-045B; TQC-2731; TQC2731 | Phase 3 Clinical | Boaoxin Biotechnology(Nanjing) Co Ltd | Nasal Polyps; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
Solrikitug | MK-8226; NSI-8226 | Phase 2 Clinical | Merck & Co Inc | Hypertension; Eosinophilic Esophagitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
Ecleralimab | CSJ-117; NOV-14 | Phase 2 Clinical | Novartis Pharma Ag | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
WIN-1001X | WIN-1001X | Phase 2 Clinical | Whanin Pharmaceutical Co Ltd | Nerve Degeneration; Parkinson Disease | Details |
PF-07275315 | PF-07275315 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
Lunsekimig | SAR-443765 | Phase 2 Clinical | Sanofi | Nasal Polyps; Asthma; Sinusitis; Inflammation; Dermatitis, Atopic | Details |
AZD-8630 | AZD-8630; AMG-104 | Phase 2 Clinical | Astrazeneca Plc, Amgen Inc | Asthma | Details |
TAVO-101 | TAVO-101; TAVO101 | Phase 2 Clinical | Tavotek Biotherapeutics (Hong Kong) Ltd | Dermatitis, Atopic; Hypersensitivity | Details |
SHR-1905 | SHR-1905; AIO-001; GSK-5784283 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Nasal Polyps; Respiratory Tract Diseases; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive | Details |
CM-326(Connaught Biomedical Technology) | CM326; CM-326 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Nasal Polyps; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
PF-06342674 | RN-168; PF-6342674; PF-06342674; ZB-168 | Phase 1 Clinical | Pfizer Inc | Diabetes Mellitus, Type 1; Multiple Sclerosis | Details |
HBM-9378 | HBM-9378; SKB378; SKB-378; A-378; WIN378; WIN-378 | Phase 1 Clinical | Harbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
HB-0056 | HB-0056; HB0056 | Phase 1 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd | Asthma | Details |
APG-333 | APG333; APG-333; PR018; PR-018 | Phase 1 Clinical | Apogee Therapeutics Inc | Asthma | Details |
SAR-444765 | SAR444765; SAR-444765 | Phase 1 Clinical | Sanofi | Inflammation | Details |
CM-512 | CM512; CM-512 | Phase 1 Clinical | Keymed Biosciences Co Ltd | Nasal Polyps; Asthma; Sinusitis; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
IBI-3002 | IBI3002; IBI-3002 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Asthma | Details |
GB-0895 | GB-0895 | Phase 1 Clinical | Generate Biomedicines Inc | Immune System Diseases; Asthma | Details |
CDX-622 | CDX-622 | Phase 1 Clinical | Celldex Therapeutics Inc | Fibrosis; Inflammation; Hypersensitivity | Details |
STSA-1201 | STSA-1201; STSA1201 | Phase 1 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Asthma | Details |
LQ043H | LQ043H | Phase 1 Clinical | Shanghai Novamab Biopharmaceuticals Co Ltd | Asthma | Details |
GR2002 | GR2002 | Phase 1 Clinical | Genrix (Shanghai) Biopharmaceutical Co Ltd | Nasal Polyps; Asthma; Sinusitis; Dermatitis, Atopic | Details |
QX-008N | QX008N; QX-008N | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
This web search service is supported by Google Inc.